Mikrobiomik

At Mikrobiomik, we are a pioneering biopharmaceutical company specializing in the development of therapies based on the gut microbiota. We are dedicated to researching, developing, and producing therapies based on the human microbiome to treat serious diseases with unmet medical needs.

Over more than eight years of research, we have developed EUTEGRA (MBK-01), a gut microbiota transplant-based therapy designed to restore the balance of the microbial ecosystem in patients with Clostridioides difficile infection.

The Phase III clinical trial ICD-01 has demonstrated the efficacy and safety of MBK-01, reinforcing our position as one of the pioneering companies in the clinical development of microbiota-based therapies in Europe and opening up new avenues for their application in other diseases associated with gut dysbiosis.

Play VideoCápsula del medicamento de MikrobiomikPlay Video

Vision

Saving lives by leading research and development into therapies based on the human microbiome.

Mision

At Mikrobiomik, we develop innovative therapies based on the gut microbiota to provide new treatment options for serious diseases with unmet medical needs.

Through our FSPIM® technology, we work to restore the balance of the microbiome and provide healthcare professionals and patients with safe, standardised and accessible therapeutic solutions for everyday clinical practice.

See Pipeline

Values

Commitment

Each member of the team is committed to find therapeutic alternatives for life-threatening diseases, always from the perspective of solutions based on the human microbiome.

01

Leadership

As leaders in Europe in the development of microbiome-based therapies, we are working to roll out this new therapeutic approach internationally.

02

Research

Research is part of our DNA, part of our culture. We devote all our efforts to searching for solutions in new indications, with the aim of expanding our pipeline.

03

Excellence

We are committed to excellence in all our processes. We produce under GMP (Good Manufacturing Practices), implement rigorous quality controls and select our donors meticulously.

04

Team

Mikrobiomik is made up of a team of expert, multidisciplinary professionals, led by highly qualified women. We focus on excellence in everything we do, with a view to developing and continuously improving our oral therapy, EUTEGRA.

“Being part of Mikrobiomik means breathing innovation and development.”

Solana P.Mikrobiomik Team
Patricia del Río - Mikrobiomik
Executive Director

Patricia del Rio

Degree in Biochemistry, Master in Cell Biology, Quality and Pharmaceutical Processes and PhD in Molecular Biology and Biomedicine.

“I love being able to transfer scientific knowledge to the development of therapies that help patients and society . Passionate about the sea, the sun and good food. The most international bilbaína of Mikrobiomik!”

Emma López - Mikrobiomik
Head of Quality Assurance - QP

Emma López

Degree in Pharmacy- Master’s degree in medicine R&D&I.

“I am in charge of the Quality Guarantee department and my signature phrase is “this is change control.”

Antonio Martínez
QP Deputy

Antonio Martínez

Doctor of Pharmacy / Official Master’s Degree in Research, Development, Control and Innovation of Medicines.

Solana Pinilla - Mikrobiomik
CFO & HR

Solana Pinilla

Degree in business administration- master in digital marketing.

“Being part of Mikrobiomik is like breath innovation and development the all time”.

Olaia Aurtenetxe - Mikrobiomik
Head of clinical research

Olaia Aurtenetxe

Degree in Biology, PhD in Molecular Biology and Biomedicine, Master in Basic and Clinical Oncology and Master in Clinical Trials.

“Science is always worth it, it is a challenging career that requires a lot of effort and dedication, therefore, I never stop challenging myself and learning”.

Ziortza Ispizua - Mikrobiomik
Production manager

Ziortza Ispizua

Senior Analysis and Control Technician.

“I am the McGyber of the company, I have a thousand stories behind my back that I solve with a cup of coffee in my hand. I safeguard the company’s Iberian secret and I like artificial intelligence”.

Nerea Rodríguez- Mikrobiomik
Quality control manager

Nerea Rodríguez

PhD in biology

“Optimistic and positive to the core, I feed on nature and sports. My phrase “Nankurunaisa al poder”.

Carlota Dopico -Mikrobiomik
Head of Business Development

Carlota Dopico

Pharmacist degree – Master in Marketing and Sales Management.

Carolina Sánchez Pastor - Mikrobiomik
QC Technician

Carolina Sánchez

Bachelor’s Degree in Clinical and Biomedical Laboratory and in Analysis and Quality Control Laboratory.

Astrid Villacorta - Mikrobiomik
Donor manager

Astrid Villacorta

Biology degree and production lab technician.

“I’m a multitasker, I process, store and chase donors, plus I always love a good chit-chat.”

Jessica Arribas Suárez- Técnico de Producción
Manufacturing Technician

Jessica Arribas

Senior Clinical Diagnostic Laboratory Technician.

María Cristina Trueba - Mikrobiomik
Production Technician

Cristina Trueba

Senior Technician in Analysis and Control

Ainara Velásquez - Mikrobiomik
Quality Assurance Technician

Ainara Velasquez

Senior Certificate in the Manufacture of Pharmaceutical, Biotechnology and Related Products.

Iría Fraga - Mikrobiomik
Quality Assurance Technician

Iría Fraga

Bachelor’s degree in Biology, Master’s degree in Biomedical Research, and further training in the field of quality management

Mayhara Camara - Mikrobiomik- Mikrobiomik
Administrativa

Mayhara Camara

Grado en Administración de Empresas

Blanca Minguet - Mikrobiomik
Market Access Specialist

Blanca Minguet

Bachelor’s degree in Pharmacy – MBA in the Pharmaceutical Industry and Biotechnology

Carlota Gómez - Mikrobiomik
Clinical Advisor

Carlota Gómez

Bachelor’s Degree in Medicine. Master’s Degree in Infectious Diseases. Master’s Degree in Advanced Clinical Care in Infectious Diseases.

Scientific Advisors Board

Rosa del Campo - Mikrobiomik
Doctor of Medicine and Surgery and Miguel Servet researcher stabilized

Rosa del Campo

Doctor of Medicine and Surgery and Miguel Servet researcher stabilized.

“Playing with bacteria to improve health.”

Jesús García-Foncilla, colaborador de Mikrobiomik
Director, Cancer Institute and Department of Oncology, Fundación Jimenez Diaz University Hospital, Autonomous University, Madrid

Jesús García-Foncillas

Director, Cancer Institute and Department of Oncology, Fundación Jimenez Diaz University Hospital, Autonomous University, Madrid.

“Only constant work beyond failure leads you to see the horizon that research brings you”.

Board Members

Guillermo Marco-Gardoqui

Co-founder at Mikrobiomik. Vice President of Operations at Grifols.

Antonio Martínez-Martínez

Co-founder at  Mikrobiomik. President in Grifols Diagnostic Division.

Juan Pedro López Araguas

Extensive experience in the Biotechnological Industry, as Director of Proteomika, COO of Progenika in the USA, Senior Advisor in the Energy and Risk Management Sector, and as Director of the country’s Health Cluster.

Facilities

Oficinas Mikrobiomik

OFFICES

Our offices are located in the BIC Bizkia intelligent building.

Laboratorio de Mikrobiomik

LABORATORY

Clean room (Grade C) designed for pharmaceutical production, adapted to meet GMP standards.

Timeline

2018: Idea

Foundation and exclusive licence for TMF with the IiSGM (Gregorio Marañón Institute of Health Research).

2019: MBK-01

Pharmaceutical development of full-spectrum gut microbiota capsules.

2020: GMP Labs

GMP facility certification by the AEMPS.

2021-2022: EECC ICD-01

Recruitment for the ICD-01 Phase III trial for C. difficile.

.

2023: Awards

‘Start-up of the Year’ award granted by El Correo and Banco Sabadell.
Toribio Echeverría Award for Best ‘Idea/Project’.
‘SME of the Year’ award granted by Banco Santander for Social Responsibility.

2024: Efficacy MBK-01

Efficacy and safety results of the EECC ICD-01 trial.

Award

International Quality Innovation Award.

2025: EECC Direbiot and LiverGut

Recruitment for both trials.
Over 100 patients received the treatment under a compassionate use program for C. difficile.

2025: Regulatory approval

Under the Soho Regulations (Substances of Human Origin).

 EUTEGRA launch

Market access in Spain for the Eutegra treatment for recurrent C. diff.